NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.50 0.00 (0.00 %)
(As of 05/21/2018 01:20 AM ET)
Previous Close$2.50
Today's Range$2.50 - $2.60
52-Week Range$2.00 - $3.95
Volume55,669 shs
Average Volume106,704 shs
Market Capitalization$44.38 million
P/E Ratio-2.19
Dividend YieldN/A
Beta2.06

About TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals logoTRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780

Debt

Debt-to-Equity Ratio0.15
Current Ratio4.24
Quick Ratio4.24

Price-To-Earnings

Trailing P/E Ratio-2.19
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.76 million
Price / Sales5.07
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book1.05

Profitability

EPS (Most Recent Fiscal Year)($1.14)
Net Income$-19,100,000.00
Net Margins-201.21%
Return on Equity-82.47%
Return on Assets-47.74%

Miscellaneous

Employees25
Outstanding Shares17,750,000

TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals (NASDAQ:TCON) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.10. The biopharmaceutical company had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 82.47%. View TRACON Pharmaceuticals' Earnings History.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for TRACON Pharmaceuticals.

What price target have analysts set for TCON?

2 Wall Street analysts have issued 1-year price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $7.00 in the next year. View Analyst Ratings for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the folowing people:
  • Dr. Charles P. Theuer, CEO, Pres & Director (Age 54)
  • Ms. Patricia L. Bitar, Chief Financial Officer, Treasurer and Assistant Sec. (Age 59)
  • Mr. H. Casey Logan, Chief Bus. Officer (Age 46)
  • Dr. Sharon Real Ph.D., Sr. VP of Product Devel. (Age 54)
  • Ms. Bonne Adams M.B.A., Sr. VP of Clinical Operations (Age 41)

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Has TRACON Pharmaceuticals been receiving favorable news coverage?

Media headlines about TCON stock have been trending somewhat positive on Monday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.39 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include PUISSANCE CROSS-BORDER OPPORTUNITIES V LLC (15.50%), NEA Management Company LLC (19.53%), Alambic Investment Management L.P. (0.52%) and X Square Capital LLC (0.45%). Company insiders that own TRACON Pharmaceuticals stock include Enterprise Associates 14 New, Peter W Sonsini, Ronald L Shazer and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Which major investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including X Square Capital LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC and Alambic Investment Management L.P.. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Enterprise Associates 14 New and Peter W Sonsini. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $2.50.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $44.38 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]harma.com.


MarketBeat Community Rating for TRACON Pharmaceuticals (TCON)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TRACON Pharmaceuticals (NASDAQ:TCON) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for TRACON Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 180.00%. The high price target for TCON is $8.00 and the low price target for TCON is $6.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$6.00$6.00$8.00
Price Target Upside: 180.00% upside135.29% upside135.29% upside213.73% upside

TRACON Pharmaceuticals (NASDAQ:TCON) Consensus Price Target History

Price Target History for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ:TCON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018Needham & Company LLCLower Price TargetBuy$8.00HighView Rating Details
6/13/2017Stifel NicolausLower Price TargetBuy ➝ Buy$14.00 ➝ $6.00HighView Rating Details
1/3/2017Wells FargoDowngradeOutperform ➝ Market PerformN/AView Rating Details
12/21/2016Jefferies GroupInitiated CoverageBuy$10.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

TRACON Pharmaceuticals (NASDAQ:TCON) Earnings History and Estimates Chart

Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ:TCON) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.19)($0.19)($0.19)

TRACON Pharmaceuticals (NASDAQ TCON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.38)N/AView Earnings Details
5/9/2018Q1 2018($0.36)($0.46)$3.00 million$3.00 millionViewN/AView Earnings Details
2/28/2018Q4 2017($0.46)($0.37)$0.71 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.25)$0.07$7.60 million$7.50 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.40)$0.81 million$0.63 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.4720)($0.44)$0.92 million$0.63 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.45)($0.45)$0.83 million$0.62 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.58)($0.48)$1.33 million$0.82 millionViewN/AView Earnings Details
8/10/2016Q2($0.62)($0.68)$1.27 million$0.81 millionViewListenView Earnings Details
5/11/2016Q1($0.70)($0.54)$1.21 millionViewListenView Earnings Details
2/18/2016Q4($0.62)($0.91)$1.40 millionViewListenView Earnings Details
11/3/2015Q3($0.51)($0.53)$1.06 million$1.18 millionViewListenView Earnings Details
8/5/2015Q215($0.42)($0.24)$1.02 million$4.20 millionViewListenView Earnings Details
5/13/2015Q1($0.37)($0.50)$1.13 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

TRACON Pharmaceuticals (NASDAQ:TCON) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 38.39%
Insider Trading History for TRACON Pharmaceuticals (NASDAQ:TCON)
Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2018Enterprise Associates 14 NewMajor ShareholderBuy707,964$2.70$1,911,502.80View SEC Filing  
6/2/2017William R LarueDirectorSell2,500$2.69$6,725.0013,388View SEC Filing  
11/29/2016Peter W SonsiniMajor ShareholderBuy869,565$5.75$4,999,998.75View SEC Filing  
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44335View SEC Filing  
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.001,497,053View SEC Filing  
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.001,498,553View SEC Filing  
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.681,503,853View SEC Filing  
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.481,503,853View SEC Filing  
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.001,507,021View SEC Filing  
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.001,528,941View SEC Filing  
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.001,544,041View SEC Filing  
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.971,551,641View SEC Filing  
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.521,573,944View SEC Filing  
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.001,573,944View SEC Filing  
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.321,613,370View SEC Filing  
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.641,655,714View SEC Filing  
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.001,715,752View SEC Filing  
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.001,715,752View SEC Filing  
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.001,715,752View SEC Filing  
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.001,740,052View SEC Filing  
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.001,755,352View SEC Filing  
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.001,769,352View SEC Filing  
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.881,772,352View SEC Filing  
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TRACON Pharmaceuticals (NASDAQ TCON) News Headlines

Source:
DateHeadline
TRACON Pharmaceuticals Expected to Post Q2 2018 Earnings of ($0.29) Per Share (TCON)TRACON Pharmaceuticals Expected to Post Q2 2018 Earnings of ($0.29) Per Share (TCON)
www.americanbankingnews.com - May 18 at 7:30 AM
Needham & Company LLC Lowers TRACON Pharmaceuticals (TCON) Price Target to $8.00Needham & Company LLC Lowers TRACON Pharmaceuticals (TCON) Price Target to $8.00
www.americanbankingnews.com - May 10 at 7:05 PM
Edited Transcript of TCON earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of TCON earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 5:55 PM
TRACON Pharmaceuticals (TCON) Releases  Earnings Results, Misses Estimates By $0.10 EPSTRACON Pharmaceuticals (TCON) Releases Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - May 10 at 4:46 PM
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2018 Results - Earnings Call TranscriptTRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:26 AM
Tracon: 1Q Earnings SnapshotTracon: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:26 AM
TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:33 PM
Comparing Heska (HSKA) and TRACON Pharmaceuticals (TCON)Comparing Heska (HSKA) and TRACON Pharmaceuticals (TCON)
www.americanbankingnews.com - May 7 at 3:56 PM
TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018
finance.yahoo.com - May 2 at 5:35 PM
TRACON Pharmaceuticals (TCON) Upgraded at ValuEngineTRACON Pharmaceuticals (TCON) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 4:20 PM
TRACON Pharmaceuticals (TCON) Set to Announce Quarterly Earnings on TuesdayTRACON Pharmaceuticals (TCON) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:40 AM
TRACON Pharmaceuticals (TCON) Rating Lowered to Sell at Zacks Investment ResearchTRACON Pharmaceuticals (TCON) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:33 PM
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted ...TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted ...
globenewswire.com - April 10 at 5:29 PM
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of DirectorsTRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
finance.yahoo.com - April 9 at 8:19 AM
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of DirectorsOncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
www.prnewswire.com - April 4 at 4:12 PM
Edited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMTEdited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:22 AM
TRACON Pharmaceuticals Inc (TCON) Major Shareholder Enterprise Associates 14 New Buys 707,964 SharesTRACON Pharmaceuticals Inc (TCON) Major Shareholder Enterprise Associates 14 New Buys 707,964 Shares
www.americanbankingnews.com - March 27 at 10:14 PM
TRACON Pharmaceutical (TCON) Announces $38.7 Million Private Placement of Common Stock and WarrantsTRACON Pharmaceutical (TCON) Announces $38.7 Million Private Placement of Common Stock and Warrants
www.streetinsider.com - March 26 at 8:24 AM
TRACON Pharma secures $38.7M capital raise; shares off 5%TRACON Pharma secures $38.7M capital raise; shares off 5%
seekingalpha.com - March 24 at 5:14 PM
TRACON Pharmaceuticals Announces $38.7 Million Private Placement - GlobeNewswire (press release)TRACON Pharmaceuticals Announces $38.7 Million Private Placement - GlobeNewswire (press release)
globenewswire.com - March 24 at 8:50 AM
TRACON Pharmaceuticals Announces $38.7 Million Private PlacementTRACON Pharmaceuticals Announces $38.7 Million Private Placement
finance.yahoo.com - March 23 at 5:41 PM
TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare ConferenceTRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 5:37 PM
TRACON Pharmaceuticals to Present at 30th Annual ROTH ... - GlobeNewswire (press release)TRACON Pharmaceuticals to Present at 30th Annual ROTH ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:19 AM
TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 7 at 8:19 AM
TRACON Pharmaceuticals to Present at 30th Annual ROTH ConferenceTRACON Pharmaceuticals to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 5:40 PM
TRACON Pharmaceuticals Inc (TCON) to Post FY2018 Earnings of $0.75 Per Share, Jefferies Group ForecastsTRACON Pharmaceuticals Inc (TCON) to Post FY2018 Earnings of $0.75 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 5 at 4:46 AM
TRACON Pharmaceuticals (TCON) Posts  Earnings Results, Beats Expectations By $0.09 EPSTRACON Pharmaceuticals (TCON) Posts Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - March 1 at 11:18 AM
Tracon Pharmaceuticals (TCON) CEO Charles Theuer on Q4 2017 ... - Seeking AlphaTracon Pharmaceuticals' (TCON) CEO Charles Theuer on Q4 2017 ... - Seeking Alpha
seekingalpha.com - March 1 at 8:16 AM
TRACON Pharmaceuticals Q4 Earnings PreviewTRACON Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - February 28 at 6:03 PM
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - February 28 at 6:03 PM
Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)
finance.yahoo.com - February 28 at 8:18 AM
Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - February 26 at 8:18 AM
$710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter$710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter
www.americanbankingnews.com - February 23 at 2:32 PM
TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018
finance.yahoo.com - February 21 at 5:26 PM
 Brokerages Expect TRACON Pharmaceuticals Inc (TCON) to Announce -$0.45 EPS Brokerages Expect TRACON Pharmaceuticals Inc (TCON) to Announce -$0.45 EPS
www.americanbankingnews.com - February 21 at 3:16 AM
TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on MondayTRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 19 at 4:44 AM
 Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00 Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00
www.americanbankingnews.com - February 6 at 10:12 AM
TRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per ShareTRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - February 4 at 3:18 AM
TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma PatientsTRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients
finance.yahoo.com - January 19 at 3:44 PM
TRACON Pharmaceuticals Reports Granting of Inducement AwardsTRACON Pharmaceuticals Reports Granting of Inducement Awards
finance.yahoo.com - January 18 at 6:17 PM
 Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - January 18 at 5:08 AM
Financial Analysis: TRACON Pharmaceuticals (TCON) & Its PeersFinancial Analysis: TRACON Pharmaceuticals (TCON) & Its Peers
www.americanbankingnews.com - January 11 at 8:18 AM
TRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment ResearchTRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 5 at 12:32 PM
Critical Survey: TRACON Pharmaceuticals (TCON) vs. Its RivalsCritical Survey: TRACON Pharmaceuticals (TCON) vs. Its Rivals
www.americanbankingnews.com - January 3 at 10:14 AM
ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:07 PM
TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 12:44 PM
Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in ChinaAmbrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China
www.bizjournals.com - December 21 at 3:39 PM
TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)
www.globenewswire.com - December 21 at 11:32 AM
35 Stocks Moving In Thursdays Pre-Market Session - Benzinga35 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - December 21 at 11:32 AM
TRACON Pharmaceuticals (TCON) and Ambrx Enter Pact for ... - StreetInsider.comTRACON Pharmaceuticals (TCON) and Ambrx Enter Pact for ... - StreetInsider.com
www.streetinsider.com - December 21 at 11:32 AM

SEC Filings

TRACON Pharmaceuticals (NASDAQ:TCON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TRACON Pharmaceuticals (NASDAQ:TCON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TRACON Pharmaceuticals (NASDAQ TCON) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.